Drulovic, Jelena (55886929900)Jelena (55886929900)DrulovicSavic, Emina (24822544200)Emina (24822544200)SavicPekmezovic, Tatjana (7003989932)Tatjana (7003989932)PekmezovicMesaros, Sarlota (7004307592)Sarlota (7004307592)MesarosStojsavljevic, Nebojsa (6603086728)Nebojsa (6603086728)StojsavljevicDujmovic-Basuroski, Irena (6701590899)Irena (6701590899)Dujmovic-BasuroskiKostic, Jelena (57159483500)Jelena (57159483500)KosticVasic, Vladimir (32467486300)Vladimir (32467486300)VasicStojkovic, Marija Mostarica (6701741422)Marija Mostarica (6701741422)StojkovicPopadic, Dusan (6602255798)Dusan (6602255798)Popadic2025-07-022025-07-022009https://doi.org/10.1016/j.jneuroim.2009.07.010https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349853050&doi=10.1016%2fj.jneuroim.2009.07.010&partnerID=40&md5=203587be535f3f818d8196b4486622a0https://remedy.med.bg.ac.rs/handle/123456789/14213We studied the effect of one-year interferon (IFN)-beta treatment on the in vivo mRNA expression of IFN-γ, interleukin (IL)-17, T-bet and RoR-γt, on peripheral blood mononuclear cells (PBMC) from 36 multiple sclerosis (MS) patients. In the total MS group, IFN-beta induced decrease in mRNA levels of IFN-γ and T-bet (p < 0.0001), while the levels of IL-17 and RoR-γt remained similar. In both responders and non-responders, IFN-beta induced significant decrease of IFN-γ (p < 0.0001 and p = 0.011, respectively), while decrease in T-bet was detected only in responders (p < 0.0001). Higher pre-treatment T-bet allowed prediction of the clinical response in the first year (β = 0.601, p = 0.036). Our preliminary findings suggest that T-bet expression might be a potential prognostic marker of treatment response to IFN-beta in MS. © 2009 Elsevier B.V. All rights reserved.IL-17Interferon-betaMultiple sclerosisRoR-γtT-betType 1 immunity